Moderna, Novavax shares dip as CDC panel suggests limiting COVID shot updates

Investing.com -- Shares of vaccine manufacturers Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) experienced slight declines in early trading on Wednesday, with Moderna down 1% and Novavax falling 1.3%.

This comes as an external panel of experts to the U.S. Centers for Disease Control and Prevention (CDC) proposed a change in vaccination recommendations on Tuesday.

The panel suggested that updated COVID-19 shots should only be given to those at risk of severe disease.

If adopted, this would be a shift from the current CDC guidelines, which recommend everyone aged six months and older receive an updated COVID-19 shot.

The proposal by the panel is still under consideration and the CDC has yet to officially change its guidelines.

The potential change could impact the demand for vaccines produced by companies like Moderna and Novavax.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.Should you invest $2,000 in NVAX right now?

With NVAX making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed NVAX alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including NVAX, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is NVAX poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now